Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) just unveiled an announcement.
Immutep Limited has announced a significant milestone in its TACTI-004 (KEYNOTE-F91) Phase III trial for treating advanced non-small cell lung cancer (NSCLC). The trial, which combines eftilagimod alfa with KEYTRUDA and chemotherapy, has enrolled over 170 patients, surpassing the number needed for futility analysis. With over 100 clinical sites activated across 24 countries, the trial is on track for a futility analysis in early 2026. This development could potentially transform the treatment landscape for NSCLC, a major cancer type with high unmet medical needs, by enhancing response rates and improving efficacy regardless of PD-L1 expression.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), with a diversified product portfolio aimed at stimulating or suppressing the immune response. Immutep is committed to bringing innovative treatment options to patients and maximizing shareholder value.
Average Trading Volume: 2,453,894
Technical Sentiment Signal: Hold
Current Market Cap: A$426.9M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.